Share

European Health Stakeholder Group Statement on the UK data protection regime

The European Health Stakeholder Group welcomes the decision on the UK data protection regime issued by the Article 93 Committee on 17 June.

EU Member States voted unanimously in favour to approve the adequacy decision which means that the flow of personal data from the EU to the UK will continue uninterrupted post-Brexit.

With just 13 days to go until the interim EU-UK data sharing agreement expires, the entire European healthcare sector can breathe a sigh of relief.

Recognition of UK data adequacy is vital for the functioning of the European health sector. It determines everything from the delivery of cross border health and social care for thousands of European citizens, to governing how health data is securely shared to advance research.

This result addresses the many and significant concerns we raised with key UK and EU decision-makers on behalf of members and the healthcare sector. Without an adequacy decision, health data flows would have stopped suddenly on 30 June unless organisations had alternative transfer mechanisms in place. The impact of this would have been felt across the entire healthcare sector, without exception and during a global pandemic.

With this decision, the EU and UK can continue to benefit from the continued secure flow of personal data to facilitate the development of new treatments and to improve patient safety and care across Europe.

It is now important that the decision is implemented before the 30 June deadline to ensure continuity in EU-UK data sharing.

Back to news list

Related News

  • EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

  • Minister F. Vandenbroucke visits EORTC Headquarters to strengthen collaborative efforts in clinical cancer research

  • IMMUcan has completed patient enrolment

  • EORTC SPRINT clinical cancer study receives support from Rising Tide Foundation to reduce the burden for patients

  • Pink October at EORTC: Over 60 years of impactful breast cancer research

  • Spotlight on ENA 2024 News

  • Do regulations and policies undermine the social value of independent academic research?

  • EORTC Quality of Life Group’s participation to ISOQOL 2024

  • New Insights into Glioblastoma Treatment for Older Adults Patients

  • TOPGEAR trial results show no significant benefit of preoperative chemoradiotherapy on long term survival